Sign up to watch this video
Free access to all Sound Bites content
Dr. Joe Mendez reviews vorasidenib for IDH mutant low-grade gliomas (Video 1/3)
Published 2 weeks
Medical Professional
INDIGO update
Related Videos
Dr. Sandip Patel discusses the impact of adding chemotherapy in patients progressing on 1L osimertinib. (Video 1/3)
Sandip Patel, MD
Dr. Laura van ‘t Veer reviews ctDNA clearance at week 3 as an early indicator in breast cancer (Video 2/3)
Laura van 't Veer, PhD
Dr. Joshua Richter discusses the MOA of CELMoDs and efficacy of MeziKd (Video 1/3)
Joshua Richter, MD
Dr. Joe Mendez reviews vorasidenib for IDH mutant low-grade gliomas (Video 1/3)
Joe Mendez, MD
Dr. Arnab Basu shares his thoughts on ctDNA-guided approaches and their impact to clinical practice today (Video 3/3)
Arnab Basu, MD
Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)
Laura van 't Veer, PhD
IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.